This is a randomized single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) in the treatment of chronic rejection in lung transplant recipients with Grade 1 or 2 BOS.~The primary endpoints will include:~Improvement or stabilization of pulmonary function test (FEV1) from baseline~Stabilization of histology (no deterioration from baseline)~Safety of the preparation~The secondary endpoints will include:~Pharmacokinetics and distribution of CsA in blood -~Change in cytokine levels from BAL specimens.
This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients with bronchiolitis obliterans syndrome (BOS).~The primary objective is to evaluate the efficacy of liposomal cyclosporine A in the treatment of chronic rejection. Pulmonary function and changes in BOS grade are the primary end points.